Pharmacodynamics

Issues of Concern

Pharmacodynamic Concepts

Pharmacodynamics describes the extent and duration of a drug's action using a few key concepts and terms:

• Emax is the maximal effect of a drug on a parameter being measured. For example, this could be a measure of platelet inhibition as an ex-vivo test or the maximum lowering of blood pressure.
• EC50 is the drug concentration at a steady state that produces half of the maximum effect. 
• Hill coefficient is the slope of the relationship between drug concentration and drug effect. Hill coefficient values above 2 indicate a steep relationship (ie, small changes in concentration produce significant changes in effect), and hill coefficient values above 3 indicate an almost instantaneous "all or none" effect.[5]

General Mechanisms of Drug Actions

Drugs produce their effects by interacting with biological targets, but the time course of the pharmacodynamic effect is dependent on the mechanism and biochemical pathway of the target. Effects can be classified as direct or indirect and immediate or delayed. Direct effects are usually the result of drugs interacting with a receptor or enzyme central to the effect's pathway. Beta-blockers inhibit receptors that directly modulate cAMP levels in smooth muscle cells in the vasculature. Indirect effects result from drugs interacting with receptors and proteins of other biologic structures significantly upstream from the end biochemical process that produces the drug effect. Corticosteroids bind to nuclear transcription factors in the cell cytosol, which translocate to the nucleus and inhibit DNA transcription to mRNA encoding for several inflammatory proteins.[6]

Immediate effects are usually secondary to direct drug effects. Neuromuscular blocking agents such as succinylcholine, which consists of 2 acetylcholine molecules linked end to end by their acetyl groups, interact with the nicotinic acetylcholine receptor on skeletal muscle cells and leave the channel in an open state, resulting in membrane depolarization and generation of an action potential, muscle contraction and then paralysis within 60 seconds after administration.[7] Delayed effects can be secondary to direct drug effects. Chemotherapy agents that interfere with DNA synthesis, like cytosine arabinoside, which is used in acute myeloid leukemia, produce bone marrow suppression that occurs several days after administration.

Dosing Principles-Based Upon Pharmacodynamics

Pharmacodynamics emphasizes dose-receptor relationships, the interactions between the drug's concentration and its effect.[8] For example, we can examine drug-receptor interactions according to the following formula:

In this equation, L represents the ligand, ie, drug concentration, R denotes receptor concentrations, and LR is the ligand-receptor complex concentrations.

Other pharmacodynamic concepts include:

Kd: The pharmacologic response depends on the drug binding to its target as well as the concentration of the drug at the receptor site. Kd measures how tightly a drug binds to its receptor. Kd is the ratio of rate constants for association (kon) and dissociation (koff) of the drug to and from the receptors. At equilibrium, the rate of receptor-drug complex formation is equal to the rate of dissociation into its components receptor + drug. The measurement of the reaction rate constants can be used to define an equilibrium or affinity constant (1/Kd). The smaller the Kd value, the greater the affinity of the antibody for its target. For example, albuterol has a Kd of 100 nanomolar (nM) for the beta-2 receptor. 

Receptor Occupancy: According to the law of mass action, the more receptors the drug occupies, the greater the pharmacodynamic response. However, all receptors need not be occupied to get a maximal response. This principle is the concept of spare receptors, which commonly includes muscarinic and nicotinic acetylcholine, steroid, and catecholamine receptors. Maximal effects are obtained by less than maximal receptor occupancy by signal amplification.

Receptor Up- and Downregulation: Chronic exposure of a receptor to an antagonist typically leads to upregulation or an increased number of receptors, while chronic exposure of a receptor to an agonist causes downregulation or decreased receptors.[9] Other mechanisms involving alteration of downstream receptor signaling may also be involved in up- or downmodulation without altering the receptor number on the cell membrane.[10] The insulin receptor undergoes downregulation due to chronic exposure to insulin. The number of surface receptors for insulin is gradually reduced by receptor internalization and degradation brought about by increased hormonal binding. An exception to the rule is the receptor for nicotine that demonstrates upregulation in receptor numbers upon extended exposure to nicotine despite nicotine being an agonist, which explains some of its addictive properties.

Effect compartment and indirect pharmacodynamics: A delay between the appearance of the drug in the plasma and its intended effect may be due to multiple factors, including transfer into the tissue or cell compartment in the body or a requirement for the inhibition or stimulation of a signal to be cascaded through intracellular pathways. These effects can be described using an effect compartment or indirect pharmacodynamic response models, which describe the drug's effect through indirect mechanisms such as inhibition or stimulation of the production or elimination of endogenous cellular components that control the effect pathway.[11]

Clinical Significance

Several issues in drug dosing can be explained in terms of Kd, receptor occupancy, and up/downregulation. Tolerance to a drug, where the effects seem to diminish with continued dosing, frequently occurs with prolonged dosing of opioids. Activation of opioid receptors stimulates the production of intracellular proteins called arrestins. Arrestins bind to the intracellular portion of the opioid receptor, block G-protein signaling, and induce receptor endocytosis. This results in less "signaling" or tolerance. The activity of arrestins, which produce receptor down-regulation, is 1 of the many pathways that lead to opioid tolerance.[10]

Enhancing Healthcare Team Outcomes

The goal of pharmacodynamics in a pharmacological therapy setting is to exert positive effects at the least necessary dose that produces the maximum therapeutic effect while minimizing the pharmacodynamics that lead to an adverse event. All interprofessional healthcare team members engaged in prescribing, dosing, dispensing, or administering pharmacological therapy must understand pharmacodynamic and pharmacokinetic principles. The level of knowledge must be commensurate with the practitioner's clinical function. However, pharmacologic therapy properly involves an interprofessional team that includes all clinicians who prescribe or order medications (MDs, DOs, NPs, PAs), pharmacists, who without question need to be the subject matter experts regarding pharmacodynamics and their application in drug therapy; clinicians should utilize them as a valuable resource because of this specialization, and nurses, who along with the pharmacists can counsel the patient about their medications, administer them in inpatient and other settings, and are often the main point of contact for patients regarding their drug regimen. An interprofessional team approach to pharmacotherapy that includes appropriate pharmacodynamic knowledge can optimize patient outcomes while minimizing adverse events.